The company’s work on immune-boosting cancer treatments is advancing especially fast, chief executive Pascal Soriot said. Photograph: Bloomberg

AstraZeneca touted an “industry-leading” line-up of hot new cancer drugs as it looked to show investors it has a strong independent future just days b(...)

Virgin America president David Cush in the New York Stock Exchange yesterday before the company’s shares’ first day of trading. Photograph: Michael Loccisano/Getty Images

European stocks were little changed as slides in healthcare and commodity stocks offset gains in media companies.Eurostat, the EU’s official number c(...)

European Central Bank president Mario Draghi says policymakers are ready to implement further stimulus measures if needed. Photograph: Ints Kalnins/Reuters

Most stocks in Europe advanced as European Central Bank president Mario Draghi said policy makers are ready to implement further stimulus measures if(...)

Pfizer tightened its full-year earnings forecast to between $2.23 and $2.27 per share from its prior outlook of $2.20 to $2.30

Pfizer reported stronger-than-expected quarterly results, helped by growing sales of its cancer drugs and demand for its medicines in emerging markets(...)

AbbVie had recently said it was still committed to the deal, which would have reduced the reliance on its Humira drug, the world’s top selling arthritis medicine which loses US patent protection in 2016

Chicago-based AbbVie said it was reconsidering its $55 billion takeover of Dublin-headquartered Shire weeks after the USgovernment moved to curb dea(...)

In London, airline stocks such as British Airways owner IAG, easyJet, cruise operator Carnival, tour operator TUI Travel and Intercontinental Hotels Group were among the top decliners on the FTSE 100 index. Photograph: Mark Wilson/Getty Images

Global equities prices fell yesterday and oil slipped to near 27-month lows as the International Monetary Fund cut its outlook for global growth and (...)

Pfizer has yet to formally put a value on the Actavis bid as it says no actual offer has been made, but it does make for a complicated chain all the same.

Keeping track of the merry-go-round that is pharma M&A is quite a challenge. It’s not all down to corporate inversion – that bête noir of US polit(...)

 Pfizer has approached Actavis to express its interest in an acquisition that could allow the US drugmaker to move overseas and reduce taxes. Photo: Bloomberg

Ireland is back at the centre of the controversy over corporate inversion as it emerged that drug giant Pfizer has approached Irish-headquartered Acta(...)

 Enda Kenny said Ireland was a place where “real companies employ very significant numbers of people”.

Ireland is “not a brass-plate location” for companies moving their residency for tax purposes and the Government has told the US it has never been a(...)

Fyffes was among the best performers in Dublin yesterday as investors gained in confidence that it may get its $1 billion proposed merger with Chiquita away, following a scheduled shareholders’ meeting next month. Photograph: Simon Dawson/Bloomberg

European shares eked out small gains in thin trading across the continent yesterday, but most European bourses closed off their morning highs, after (...)